Mechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease

被引:0
|
作者
Chris Cadonic
Mohammad Golam Sabbir
Benedict C. Albensi
机构
[1] St. Boniface Hospital Research,Graduate Program in Biomedical Engineering, Faculties of Health Sciences, Engineering, and Science
[2] University of Manitoba,Department of Pharmacology & Therapeutics
[3] University of Manitoba,undefined
来源
Molecular Neurobiology | 2016年 / 53卷
关键词
Mitochondria; Alzheimer’s disease; Review; Electron transport chain; Mitochondrial dysfunction;
D O I
暂无
中图分类号
学科分类号
摘要
Mitochondria are the primary source for energy generation in the cell, which manifests itself in the form of the adenosine triphosphate (ATP). Nicotinamide dinucleotide (NADH) molecules are the first to enter the so-called electron transport chain or ETC of the mitochondria. The ETC represents a chain of reducing agents organized into four major protein-metal complexes (I-IV) that utilize the flow of electrons to drive the production of ATP. An additional integral protein that is related to oxidative phosphorylation is ATP synthase, referred to as complex V. Complex V carries out ATP synthesis as a result of the electron flow through the ETC. The coupling of electron flow from NADH to molecular oxygen to the production of ATP represents a process known as oxidative phosphorylation. In this review, we describe mainly the bioenergetic properties of mitochondria, such as those found in the ETC that may be altered in Alzheimer’s disease (AD). Increasing evidence points to several mitochondrial functions that are affected in AD. Furthermore, it is becoming apparent that mitochondria are a potential target for treatment in early-stage AD. With growing interest in the mitochondria as a target for AD, it has been hypothesized that deficit in this organelle may be at the heart of the progression of AD itself. The role of mitochondria in AD may be significant and is emerging as a main area of AD research.
引用
收藏
页码:6078 / 6090
页数:12
相关论文
共 50 条
  • [41] Mechanisms of Neural and Behavioral Dysfunction in Alzheimer’s Disease
    Daniel W. Wesson
    Ralph A. Nixon
    Efrat Levy
    Donald A. Wilson
    Molecular Neurobiology, 2011, 43
  • [42] Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer's disease
    Gu, Xue-Mei
    Huang, Han-Chang
    Jiang, Zhao-Feng
    NEUROSCIENCE BULLETIN, 2012, 28 (05) : 631 - 640
  • [43] Neuronal Calcium Signaling, Mitochondrial Dysfunction, and Alzheimer's Disease
    Supnet, Charlene
    Bezprozvanny, Ilya
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 20 : S487 - S498
  • [44] Mitochondrial dysfunction in Alzheimer's disease-a proteomics perspective
    Abyadeh, Morteza
    Gupta, Vivek
    Chitranshi, Nitin
    Gupta, Veer
    Wu, Yunqi
    Saks, Danit
    Wander Wall, Roshana
    Fitzhenry, Matthew J.
    Basavarajappa, Devaraj
    You, Yuyi
    Salekdeh, Ghasem H.
    Haynes, Paul a
    Graham, Stuart L.
    Mirzaei, Mehdi
    EXPERT REVIEW OF PROTEOMICS, 2021, 18 (04) : 295 - 304
  • [45] Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease
    Eckert, A
    Keil, U
    Marques, CA
    Bonert, A
    Frey, C
    Schüssel, K
    Müller, WE
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (08) : 1627 - 1634
  • [46] Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease
    Anandatheerthavarada, Hindupur K.
    Devi, Latha
    NEUROSCIENTIST, 2007, 13 (06): : 626 - 638
  • [47] Mitochondrial Dysfunction: Different Routes to Alzheimer's Disease Therapy
    Picone, Pasquale
    Nuzzo, Domenico
    Caruana, Luca
    Scafidi, Valeria
    Di Carlo, Marta
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2014, 2014
  • [48] Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
    Singulani, Monique P.
    De Paula, Vanessa J. R.
    Forlenza, Orestes, V
    NEUROSCIENCE LETTERS, 2021, 760
  • [49] Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development
    Bhatia, Shiveena
    Rawal, Rishi
    Sharma, Pratibha
    Singh, Tanveer
    Singh, Manjinder
    Singh, Varinder
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (04) : 675 - 692
  • [50] Mitochondrial dysfunction as an emerging preclinical concept of Alzheimer's disease
    Rhein, V.
    Baysang, G.
    Meier, F.
    Ozmen, L.
    Bluethmann, H.
    Mueller-Spahn, F.
    Czech, C.
    Goetz, J.
    Eckert, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S92 - S92